Majallah-i Dānishkadah-i ̒ulūm-i Pizishkī-i Niyshābūr (May 2016)
Effect of Pamidronate on Hypercalcemia, BUN and Cr in Patients with Malignancy
Abstract
Introduction and Aims Bone metastases have bad potential effects on the individual life period. One of these complications is hypercalcemia that cause dizziness, nausea, constipation and azotemia. Pamidronate reduces skeletal complications in patients with bone metastases. This study evaluated effect of Pamidronate on hypercalcemia BUN and Cr in cancer patients. Materials and Methods In this quasi-experimental study, 41 patients with malignancy referring to Ramsar Imam Sajjad hospital were selected by convenience sampling. In this study 90 mg of Pamidronate was injected intravenously monthly for 3 months. Data collection was done through demographic and clinical data questionnaire and blood samples. Data of before and after intervention were compared. Statistical analysis was performed using paired t tests, chi-square, Friedman and Wilcoxon tests with SPSS v.11.5 and P<0.05 was considered as significant. Results The most common cancer was breast (43.9%) and bone metastasis point in most patients (65.9%) was diffuse. The results of this study indicated that there was significant difference between serum Ca (calcium) (P=0.015), BUN (Blood Urea Nitrogen) (P=0.031), ALKP (Alkalin Phosphatase) (P=0.002) before and after treatment, but there was no significant difference between Cr (Creatinine) concentration before and after treatment (P=0.41). Conclusion Pamidronate is effective in prevention of hypercalcemia and decrease BUN and Cr. So, it can be used as main and routine treatment. * Corresponding Author: Tonekabon Branch, Islamic Azad University, Faculty of Medicine. Email: [email protected]
